← back to search

Charlotta Ljungman

Copenhagen University Hospital · SE
Area of research
Cardiology and Cardiovascular Medicine · Endocrinology, Diabetes and Metabolism
Research interest
Research interests include Heart Failure Treatment and Management, Diabetes Treatment and Management, Cardiovascular Function and Risk Factors, and Blood Pressure and Hypertension Studies.
h-index
21
citations
8,889
works
103
NIH funding
primary concept
Medicine
email

Recent publications

Characteristics and Outcomes of Patients with Heart Failure and History of Malignancy: Data from Swedish Heart Failure Registry and the National Cancer Register
European Journal of Heart Failure 2025cited by 5position: middledoi
Iron Deficiency Definitions in Heart Failure Across Ejection Fraction Phenotypes
JACC Heart Failure 2025cited by 4position: middledoi
Fatty liver disease, heart rate and cardiac remodelling: Evidence from the <scp>UK</scp> Biobank
Liver International 2023cited by 19position: middledoi
Reply to: “Fatty liver disease at the basis of cardiac remodelling and increased heart rate: Insights from the UK Biobank”
Liver International 2023cited by 0position: middledoi
Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction
JAMA Cardiology 2021cited by 47position: middledoi
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
JAMA 2020cited by 529position: middledoi
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
European Heart Journal 2020cited by 194position: middledoi
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)
European Heart Journal 2020cited by 133position: middledoi
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
New England Journal of Medicine 2019cited by 6,746position: middledoi
Gender differences in antihypertensive drug treatment: results from the Swedish Primary Care Cardiovascular Database (SPCCD)
Journal of the American Society of Hypertension 2014cited by 69position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Mirta Díez · Instituto Cardiovascular de Buenos Aires2 papers (2020–2021)Mikhail Kosiborod · Nagoya University2 papers (2020–2021)Scott D. Solomon · Harvard University2 papers (2020–2021)Lars H. Lund · Associazione Nazionale Medici Cardiologi Ospedalieri2 papers (2025–2025)Tzvetana Katova · Clinical Trial Investigators2 papers (2020–2021)Felix Lindberg · Karolinska University Hospital2 papers (2025–2025)Federica Tavaglione · Agostino Gemelli University Polyclinic2 papers (2023–2023)Kieran F. Docherty · University of Glasgow2 papers (2020–2021)Mark C. Petrie · King's College London2 papers (2020–2021)Oveis Jamialahmadi · Karolinska Institutet2 papers (2023–2023)Anna Maria Langkilde · AstraZeneca (Brazil)2 papers (2020–2021)Gianluigi Savarese · Karolinska University Hospital2 papers (2025–2025)Piotr Ponikowski · University of Business in Wrocław2 papers (2020–2021)Pardeep S. Jhund · Harvard University2 papers (2020–2021)Stefano Romeo · Karolinska University Hospital2 papers (2023–2023)Olof Bengtsson · University of Glasgow2 papers (2020–2021)John J.V. McMurray · University of Glasgow2 papers (2020–2021)Eileen O’Meara · Montreal Heart Institute2 papers (2020–2021)Marc S. Sabatine · Smart Material (Germany)2 papers (2020–2021)Mikaela Sjöstrand · AstraZeneca (Sweden)2 papers (2020–2021)